Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) will likely be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($2.38) per share and revenue of $5.30 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing the consensus estimate of ($3.16) by ($0.82). The business had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%. On average, analysts expect Tonix Pharmaceuticals to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock traded up $0.02 on Monday, hitting $13.62. 254,563 shares of the company’s stock were exchanged, compared to its average volume of 406,189. The company has a 50-day simple moving average of $13.77 and a 200-day simple moving average of $15.95. The stock has a market capitalization of $182.56 million, a PE ratio of -0.95 and a beta of 1.68. Tonix Pharmaceuticals has a 1 year low of $11.60 and a 1 year high of $69.97.

Insider Transactions at Tonix Pharmaceuticals

In related news, CEO Seth Lederman purchased 15,000 shares of Tonix Pharmaceuticals stock in a transaction on Wednesday, March 18th. The shares were bought at an average cost of $14.89 per share, for a total transaction of $223,350.00. Following the acquisition, the chief executive officer owned 15,001 shares in the company, valued at approximately $223,364.89. The trade was a 1,500,000.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of Tonix Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada bought a new stake in shares of Tonix Pharmaceuticals in the 1st quarter worth about $610,000. Geode Capital Management LLC increased its holdings in shares of Tonix Pharmaceuticals by 182.4% in the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock worth $6,305,000 after buying an additional 113,175 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter worth about $129,000. Legal & General Group Plc bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter worth about $25,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter worth about $104,000. 82.26% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TNXP has been the topic of several analyst reports. TD Cowen initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $22.00 price target on the stock. Wall Street Zen downgraded shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.